Australia's Cleo Diagnostics jumps on US clinical trials for cancer blood test
06/09/2024 02:13
** Shares of Cleo Diagnostics COV.AX rise as much as 4.2%
to A$0.375, set for best days since Aug. 26, if gains hold
** Cancer diagnostics co announces commencement of U.S.
clinical trials for its ovarian cancer diagnostic blood test
** Trial will validate the use of the ovarian cancer blood
test for the U.S. market - co
** COV up 105.7% YTD as of last close
(Reporting by Adwitiya Srivastava in Bengaluru)
((Adwitiya.Srivastava@thomsonreuters.com;))
Recent news on CLEO Diagnostics
See all newsAustralia's Cleo Diagnostics jumps after cancer screening test meets milestone
Brief: Cleo Diagnostics Files Patents For Its Ovarian Cancer Screening Test
Australia's Cleo Diagnostics jumps as ovarian cancer test hits validation milestone
Brief: Cleo Diagnostics Receives First Batch Of Commercially Manufactured Test Kits
Brief: Cleo Diagnostics Raises A$5M